Next-Generation Sequencing in Drug Discovery Market Dynamics Influenced by Precision Medicine and Personalized Therapeutics

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Next-Generation Sequencing in Drug Discovery Market Size, Share & Trends Analysis Report Product Type (Instruments, Consumables, and Software & Services) By Technology (Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, Chip-Sequencing (ChIP-Seq), and De Novo Sequencing) By Application (Drug Target Identification, Pharmacogenomics, Toxicogenomic, and Clinical Trial Stratification) By End-User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Hospitals & Clinics) By Workflow (Sample Preparation, Sequencing, Data Analysis, and Data Interpretation)-Market Outlook And Industry Analysis 2034"

Next-Generation Sequencing in Drug Discovery Market Size is valued at US$ 1.3 Bn in 2024 and is predicted to reach US$ 7.5 Bn by the year 2034 at an 19.7% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/3176

Next-generation sequencing (NGS) in drug discovery is a high-throughput DNA sequencing technology utilized for rapid analysis of genetic variations, identification of drug targets, and elucidation of disease mechanisms, thereby enabling the development of targeted and effective therapeutics.

The technology's increasing adoption in precision medicine and targeted therapies is driving market growth. NGS supports comprehensive genomic analysis, allowing for the detection of disease-associated mutations and biomarkers, which accelerates drug development, reduces costs, and enhances treatment efficacy.

The growth of NGS in drug discovery is further propelled by its ability to deliver accurate, high-throughput genetic data, facilitating accelerated target discovery and biomarker identification. Its scalability and cost efficiency allow for rapid screening of drug candidates. Additionally, its application in rare disease research is a key driver, as NGS enables the detection of rare genetic variants, supporting the development of personalized therapies. This capability expands drug development pipelines and optimizes treatment outcomes for diseases that were previously difficult to treat.

List of Prominent Players in the Next-Generation Sequencing in Drug Discovery Market:
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• Agilent Technologies, Inc.
1. Hoffmann-La Roche Ltd. (Roche)
• QIAGEN N.V
• BGI Genomics Co., Ltd.
• Bio-Rad Laboratories, Inc.
• Oxford Nanopore Technologies plc
• Pacific Biosciences of California, Inc. (PacBio)
• PerkinElmer, Inc.
• Genapsys, Inc.
• Eurofins Scientific
• Macrogen, Inc.
• Takara Bio Inc.
• DNAnexus, Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics:
Drivers:
The next-generation sequencing (NGS) market in drug discovery is experiencing significant growth, driven by increasing investments in biopharmaceutical research and development. Pharmaceutical and biotechnology companies are allocating substantial resources to advanced genomic technologies to accelerate the identification of drug targets and streamline therapeutic development.

NGS enables high-throughput sequencing of genetic material, allowing researchers to map disease-causing mutations, uncover novel drug targets, and develop personalized treatment strategies. Its high accuracy and throughput are transforming preclinical and clinical research workflows, reducing development timelines and associated costs. Moreover, both public and private funding initiatives for precision medicine and genomic research are fostering innovation, positioning NGS as a critical technology for the future of drug development.

Challenges:
Despite its transformative potential, the adoption of NGS in drug discovery faces challenges in low-resource settings. High costs, limited infrastructure, and a shortage of skilled professionals restrict access in developing regions. Establishing and maintaining NGS platforms requires significant investment in equipment, reagents, and computational infrastructure, which can be prohibitive for smaller research facilities.

Additionally, inadequate internet connectivity and limited bioinformatics capabilities hinder data analysis and interpretation, constraining large-scale implementation and restricting global access to NGS-enabled drug discovery, particularly in regions with urgent needs for therapies targeting genetic and infectious diseases.

Regional Trends:
North America, led by the United States, dominates the global NGS market in drug discovery. The region benefits from strong demand for precision medicine, growing R&D expenditures, and advanced genomic technologies. Pharmaceutical and biotechnology firms leverage NGS to accelerate biomarker discovery, identify novel drug targets, and optimize clinical trial design.

Government support, including NIH grants and favorable regulatory frameworks for genomic research, further drives market growth. The presence of a robust healthcare infrastructure and major industry stakeholders underpins widespread adoption of NGS in early-stage drug development.

In Europe, market growth is fueled by advancements in genomic research and rising demand for personalized medicine. NGS facilitates high-throughput analysis of genetic variations, enhancing the accuracy of target and biomarker discovery for pharmaceutical companies. Initiatives such as Horizon Europe and national genome projects support increased R&D investment, while collaborations between universities and biotechnology firms promote the integration of NGS technologies into early drug discovery processes.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customization/3176

Recent Developments:
• February 2025: Roche launched its proprietary, breakthrough sequencing by expansion (SBX) technology, establishing a new segment of next-generation sequencing. SBX chemistry, along with a creative sensor module, provides ultra-rapid, high-throughput sequencing that is both flexible and scalable for a broad range of applications.
• April 2024: Bio-Rad Laboratories, Inc. Incannounced a collaboration agreement with Oncocyte Corporation, a precision diagnostics firm, to develop and commercialize transplant monitoring products utilizing Bio-Rad's Droplet DigitalTM PCR (ddPCRTM) instruments and reagents.

Segmentation of Next-Generation Sequencing in Drug Discovery Market-
By Product Type-
• Instruments
• Consumables
• Software & Services
By Technology -
• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing
• Chip-Sequencing (ChIP-Seq)
• De Novo Sequencing
By Application-
• Drug Target Identification
• Pharmacogenomics
• Toxicogenomic
• Clinical Trial Stratification
By End-user-
• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Contract Research Organizations (CROs)
• Hospitals & Clinics
By Workflow-
• Sample Preparation
• Sequencing
• Data Analysis
• Data Interpretation
By Region-
North America-
• The US
• Canada
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Mexico
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/next-generation-sequencing-in-drug-discovery-market/3176

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.